Список литературы

2687-0940

Challenges in modern medicine

2687-0940

10.52575/2687-0940-2022-45-4-319-324

128

INTERNAL DISEASES

<strong>Clinical Case of Rheumatoid Seronegative Polyarthritis Against the Background of Latent Tuberculosis Infection</strong><br />  

Fentisov

Vitaly V.

Fentisov

Vitaly V.

fentisov@bsuedu.ru

2022

45400

A clinical example of a combined pathology of rheumatoid arthritis and latent tuberculosis infection is presented. Before being included in the program of genetically engineered biological therapy for rheumatoid arthritis, immunological screening for the presence of latent tuberculosis infection was carried out. Properly organized immunological diagnosis of tuberculosis in tuberculosis risk groups contributed to the early detection of a patient with latent tuberculosis infection. The preventive course of anti-tuberculosis therapy made it possible to start treatment of rheumatoid arthritis with immunosuppressive pills, reducing the risk of activation of tuberculosis infection.

rheumatoid arthritisgenetically engineered biological therapylatent tuberculosis infection

Список литературы

References

Artemiev A. A. 2017. Vliyaniye defektov vedeniya bol'nykh v obshchey lechebnoy seti na formirovaniye lekarstvennoy ustoychivosti MBT [The influence of defects in patient management in the general medical network on the formation of MBT drug resistance]. Byulleten' meditsinskikh internet-konferentsiy. 7 (5): 759.

Bogorodskaya E.M., Slogockaya L.V., Belilovskij E.M., Roshchupkina O.M. 2017. Latentnaya tuberkuleznaya infektsiya v gruppakh riska u vzroslogo naseleniya goroda Moskvy, 2012–2016 gg. [Latent tuberculosis infection in risk groups in the adult population of Moscow, 2012–2016]. Tuberkulez i sotsial'no-znachimyye zabolevaniya. (2): 10–15.

Dementieva E.K., Aksenova V.A., Klevno N.I., Kazakov A.V. 2021. Sovremennyye podkhody k profilaktike tuberkuloza u patsiyentov, poluchayushchikh immunodepressanty [Modern approaches to the prevention of tuberculosis in patients receiving immunosuppressants]. Rossiyskiy pediatricheskiy zhurnal. 24 (S): 19–20.

Makarova N.V., Borisov S.E., Frolova K.S. 2021. Kontrol' tuberkuleznoy infektsii pri lechenii biologicheskimi i targetnymi sinteticheskimi preparatami. [Tuberculosis infection control during treatment with biological and targeted synthetic drugs.] Tuberkulez i sotsial'no-znachimyye zabolevaniya. (1): 72–73.

Muchaidze R., Dantsev V., Zaretskii B., Spitsyn M., Svintsitskaya I. 2021. Aktual'nost' i problemy profilaktiki tuberkuleza u patsiyentov, poluchayushchikh lecheniye genno-inzhenernymi biologicheskimi preparatam [Relevance and problems of tuberculosis prevention in patients receiving treatment with genetically engineered biological drugs]. Meditsinskiy al'yans. 9 (3):

22–30. doi: 10.36422/23076348-2021-9-3-22-30

Myakisheva T.V., Avdeeva T.G., Rashkevich E.E. 2015. Deti s revmatoidnym artritom kak immunokomprometirovannaya gruppa riska po tuberkulezu [Children with rheumatoid arthritis as an immunocompromised risk group for tuberculosis] Tuberkulez i bolezni legkikh. (6): 103–104.

Nasonov E.L. 2016. Perspektivy farmakoterapii revmatoidnogo artrita: novyye vozmozhnosti i rekomendatsii [Perspectives on the pharmacotherapy of rheumatoid arthritis: new opportunities and recommendations]. Terapevticheskiy arkhiv, 88 (12): 4–10.

Pavlunin A.V., Sharafutdinova M.A., Borisova S.B., Mishanov R.F., Medovarov E.V. 2014. Problemy organizatsii vyyavleniya i diagnostiki tuberkuleza legkikh v obshchey lechebnoy seti [Problems of organizing the detection and diagnosis of pulmonary tuberculosis in the general medical network]. Tuberkulez i bolezni legkikh. (11): 18–22.

Sakenova M.M., Perevezenceva V.M., Rahimova S.S., Erezhepova M.M. 2022. Otsenka priverzhennosti k lecheniyu bazisnymi protivovospalitel'nymi preparatami u bol'nykh s revmatoidnym artritom [Assessment of adherence to treatment with basic anti-inflammatory drugs in patients with rheumatoid arthritis] Tendentsii razvitiya nauki i obrazovaniya. 85 (9): 98–100.

Fentisov V.V. 2022. Sravnitel'noye issledovaniye pokazateley zabolevayemosti tuberkulezom vzroslogo naseleniya po vozrastnomu i polovomu priznaku [Comparative study of tuberculosis incidence rates in the adult population by age and gender]. Sovremennyye problemy nauki i obrazovaniya. (3): 117.

Shevchenko A.I., Drobot N.N., Kondrat'eva E.G. 2022. Konsolidatsiya deyatel'nosti vrachey ftiziatricheskoy sluzhby i obshchey lechebnoy seti v vyyavlenii tuberkuleza legkikh. Mezhdunarodnyy nauchno-issledovatel'skiy zhurnal [Consolidation of the activities of doctors of the TB service and the general medical network in the detection of pulmonary tuberculosis]. Mezhdunarodnyy nauchno-issledovatel'skiy zhurnal. 4–2 (118): 89–93. DOI: 10.23670/IRJ.2022.118.4.087

Malaviya A.N., Aggarwal V.K., Rawat R., Baghel S., Thakran R., Zaheer Q., Garg S., Kapoor S. 2018. Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon-TB Gold tests. Int. J. Rheum. Dis. 21 (8): 1563–1571.

Malinová J., Hájková M., Hatalová A., &Scaron;teňová E. 2022. Risk of latent tuberculosis in the cohort of patients with rheumatoid arthritis in Slovakia. Epidemiol Mikrobiol Imunol. Summer; 70 (2): 83–90.

Oulkadi L., Rostom S., Hmamouchi I., El Hassani Sbai S., El Binoune I., Amine B., Abouqal R., Allali F., Achemlal L., El Bouchti I., El Maghraoui A., Ghozlani I., Hassikou H., Harzy T., Ichchou L., Mkinsi O., Niamane R., Bahiri R. 2021. Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registry. Rheumatol Int. 41 (9): 1625–1631.

Song Y.J., Cho S.K., Kim H., Kim H.W., Nam E., Bae S.C., Yoo D.H., Sung Y.K. 2021. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study. J. Korean. Med. Sci. 36 (10): e70.